Member Info for Fruitsnveg

Josh, this is what I've found on it - tbh it doesn't sound like very strong results to me.
"AstraZeneca Plc’s antibody ****tail was only 33% effective at preventing Covid-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker’s pandemic push. The trial of 1,121 adult volunteers looked at whether the long-acting antibody combination could protect people who had recently been in contact with the SARS-CoV-2 virus in places like care homes. The company said it’s running other studies of the medicine that could help clarify the findings."

And this: https://www.clinicaltrialsarena.com/news/astrazeneca-covid-drug-trial-data/ which states "AstraZeneca’s Covid-19 drug candidate fails in Phase III study"

I don't see it as market sensitive and would be surprised if that was RNS'd. Last patient dosed doesn't move the dial a jot. Data, and only data counts.
-> Every company will be able to say they had a 'last patient dosed', few will be able to report successful trial data off the back of it. As always, I hope we are one of those few. GLA.

I wondered the same....I don't know the answer but would be keen to know too.

Activ-2: "We have finished our phase 2 studies (with this last surge)"

Smiley face. Now it's up to the data. Go Synairgen.

I too am starting to notice it amongst mask-wearing double jabbed friends kids (in particular the <12's), which is concerning. Many holiday-makers still abroad and yet to return, much like our part-time governmental ministers. Add RSV and flu into the mix and I'd be surprised, very surprised, if there are functioning primary-age classrooms by November. I pity the parents of the 1+ million young kids on asthma medication, not to mention the many ill others for whom 'letting it rip' is not a humane option. This approach is beyond baffling.

Sorry TLWilliams, I hadn't checked, you are correct. Best to google it as you suggest as it contains graphs etc, but well worth a read I think. GL.

https://www.ft.com/content/49641651-e10a-45f6-a7cc-8b8c7b7a9710

Interesting research.

Wise words Welshfalcon.

Kevin, I see you are invested in ARB too - as you are aware the 2 shares could not be further apart and operate in completely different galaxies ref: front of house, news cycles etc etc. If you are not a day trader it's easy to get hooked on the quick crypto buck/Peter Wall slickness, which I'm hoping has temporarily clouded your view and led to, IMO, unecessary and futile impatience. All signs here are pointing in the right direction here IMO - worth waiting for.

Without a doubt Woodstock.

I doubt it. I think this will be a regular occurrence until that "event-driven" news drop. As long as our large new investor can sell into the negative doubt-inducing guff that was pushed on the BB from 10am , then there's money to be made. No coincidence. Who, why, timings - that's all you need to watch.
GLA.

Hi Alkin, I think you misunderstand my sentiment on this, I think we're on the same side. I'm a LTH who believes this BOD, company, and the science behind their drug. I'm not knocking Synairgen or the P3 trial outcome, I expect it to be good and I want the company in t's current guise to see success. Not everyone does though and will exploit even the merest hint of unwelcome news. I am acknowledging that, that's all.

Agree Doc, some events will drive negative sentiment, something investors with enough of a stake (say 10%+) might willingly embrace and exploit to their advantage. Profit works both ways. Thanks TLWilliams for the heads up about Polygon interplay with Watchstone Group BOD and investors (WTG), one to watch IMO...

With due respect Alkin, I disagree. You are assuming there will be no *perceived* delay or any level of *ambiguity* with results, something that has historically been manipulated with much success on this BB, much like others. Discord is a wonderful sledge to hammer the SP. Until good P3 results are released, it matters.

https://www.theguardian.com/world/2021/aug/09/think-its-all-over-uk-coronavirus-experts-are-not-so-sure-covid-remains-unpredictable

"“I’ve just done a ward round and my entire infection ward is mainly Covid,” he said, citing a mix of vaccinated and unvaccinated patients. “Seeing how sick some of these people have been, it is really … quite discordant with what is happening in society where everyone is going out [thinking Covid] is not a problem any more.
It’s too early to be saying it’s all over,” said Gupta. “And seeing the degree of lung damage [on patients’ scans], it is very sobering to think that the government could have said, this is OK, for large numbers of people [to get Covid].”
- Prof Ravi Gupta of the University of Cambridge, a co-opted member of the New and Emerging Respiratory Virus Threats Advisory Group that advises the government.

Dibs, TL, I'm glad to see others finally starting to research this investor to ascertain their possible MO here. People need to wake up or have the rug pulled out from under them. I do not view their investment here as friendly and never have. What you see with WTG is a taster. There's plenty on the internet to help form a view. I hope I'm wrong. DYOR.

On a completely separate note, odd that you should mention it, but I was an original investor of the scandalous Quindell. The mere mention of the old company name still makes my hairs bristle... Let's say it fine-tuned by BS detector - if it walks like a duck, and it quacks like a duck, rest assured - it's a duck. Always trust your instinct. GLA.

Very good synopsis JoeyDiamond and a critical point made: "The drugs primary target in the treatment course is different."

If I may add, people who invest in Pepsi don't necessarily invest in craft beer. Both are drinks, but both are different. Thus it isn't a question of Molnupiravir *versus* SNG001, something investors are well aware of. It's a question of having enough tools in the toolkit to fight the fight. Both drugs if they pass muster are needed, plus many more IMO...

On a separate note, I don't think it's inconceivable that Merck would be interested in Synairgen's offering. I've long thought them a good fit. Great hedge for them too. Just my opinion but one I can't quite shake off....

Funny that. Last time polygon bought the derampers arrived with the same old tunes. Somewhere, dots are connecting.

Not necessarily. Event driven doesn't just mean they are waiting for 'good' news. Some will be waiting like sharks for a cheap meal on spilled blood. I remain cautious about this investor until their MO is understood. Friend or foe, who knows....

That was Decca records Doc. Bet they're still kicking themselves...